These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3956687)

  • 1. The biologically active conformation of ergot alkaloids.
    Kidric J; Kocjan D; Hadzi D
    Experientia; 1986 Mar; 42(3):327-8. PubMed ID: 3956687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological basis for the therapeutic use of ergot alkaloids].
    Tran MA; Montastruc JL; Montastruc P
    Presse Med; 1983 Feb; 12(8):517-20. PubMed ID: 6131414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple CNS receptor interactions of ergot alkaloids: affinity and intrinsic activity analysis in in vitro binding systems.
    U'Prichard DC
    Adv Biochem Psychopharmacol; 1980; 23():103-15. PubMed ID: 6249089
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopaminergic activity of some ergot alkaloid derivatives: relationship to their chemical structure.
    Soskić V; Petrović J; Trajković D; Kidric M
    Pharmacology; 1986; 32(3):157-66. PubMed ID: 2938196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ergot alkaloids. Synthesis of 6-alkyl-8-ergolenes and 6-methyl-8-aminoergolines as potential prolactin inhibitors.
    Crider AM; Robinson JM; Floss HG; Cassady JM; Clemens JA
    J Med Chem; 1977 Nov; 20(11):1473-7. PubMed ID: 915908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding interactions of ergot alkaloids with monoaminergic receptors in the brain.
    Goldstein M; Lew JY; Hata F; Lieberman A
    Gerontology; 1978; 24 Suppl 1():76-85. PubMed ID: 22480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the antagonism of ergot alkaloids and dopamine by phenothiazines.
    Stone TW
    Experientia; 1974 Jul; 30(7):827-9. PubMed ID: 4847689
    [No Abstract]   [Full Text] [Related]  

  • 8. Dopaminephilic properties of ergot alkaloids.
    Goldstein M; Lew JY; Nakamura S; Battista AF; Lieberman A; Fuxe K
    Fed Proc; 1978 Jun; 37(8):2202-6. PubMed ID: 26607
    [No Abstract]   [Full Text] [Related]  

  • 9. Alkaloid binding and activation of D2 dopamine receptors in cell culture.
    Larson BT; Harmon DL; Piper EL; Griffis LM; Bush LP
    J Anim Sci; 1999 Apr; 77(4):942-7. PubMed ID: 10328360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of ergot alkaloids with dopaminergic receptors in the rat striatum and nucleus accumbens.
    Spano PF; Trabucchi M
    Gerontology; 1978; 24 Suppl 1():106-14. PubMed ID: 618775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural modifications of the ergopeptine molecule and their differential influence on the affinities to different receptor binding sites--a structure affinity analysis.
    Closse A; Bolliger G; Dravid A; Frick W; Hauser D; Pfäffli P; Sauter A; Tobler HJ
    Adv Biochem Psychopharmacol; 1983; 36():269-79. PubMed ID: 6305153
    [No Abstract]   [Full Text] [Related]  

  • 12. Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole.
    Andersen K; Liljefors T; Hyttel J; Perregaard J
    J Med Chem; 1996 Sep; 39(19):3723-38. PubMed ID: 8809161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ergot alkaloids and some problems of the physiology of their formation.
    Rehácek Z
    Zentralbl Bakteriol Parasitenkd Infektionskr Hyg; 1974; 129(1):20-49. PubMed ID: 4152878
    [No Abstract]   [Full Text] [Related]  

  • 14. Interactions of ergot compounds with dopamine receptors and endocrine functions.
    Flückiger E
    J Neural Transm Suppl; 1983; 18():189-204. PubMed ID: 6576114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxicity and accumulation of ergot alkaloids in human primary cells.
    Mulac D; Humpf HU
    Toxicology; 2011 Apr; 282(3):112-21. PubMed ID: 21295106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ergoline derivatives: receptor affinity and selectivity.
    Mantegani S; Brambilla E; Varasi M
    Farmaco; 1999 May; 54(5):288-96. PubMed ID: 10418123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors.
    Sibley DR; Creese I
    Mol Pharmacol; 1983 May; 23(3):585-93. PubMed ID: 6223205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the interaction of the aromatic part of dopaminergic agonists with the receptor.
    Kocjan D
    J Med Chem; 1994 Sep; 37(18):2851-5. PubMed ID: 7915324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of GYKI-32 887 on dopamine (D2) and serotonin (5-HT1 and 5-HT2) receptors.
    Berzétei IP; Bagdy E; Hardy M; Borsy J
    Pol J Pharmacol Pharm; 1985; 37(3):237-42. PubMed ID: 4070077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformationally restricted dopamine congeners--a molecular mechanics-based study.
    Kocjan D; Hadzi D
    J Pharm Pharmacol; 1983 Dec; 35(12):780-5. PubMed ID: 6141239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.